Antisense Therapeutics Limited

ASX Code



Pharmaceuticals- Biotechnology & Life Sciences

Investor Centre





Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.


Antisense Therapeutics (ASX:ANP) - Webinar Presentation
ASX closes 0.85% higher: Rio Tintos half-year profit gets slammed
ASX up 0.75% at noon: June quarter inflation lower than expected
Stocks of the Hour: QX Resources, Antisense Therapeutics, West Wits Mining
Antisense Taking a Quick Approach to Long COVID
ANP - Morgans rates the stock as Speculative Buy
Antisense Therapeutics: The pathway to commercialisation
Due Diligence Webinar - Antisense Therapeutics (ASX: ANP)
Antisense Therapeutics (ASX: ANP) - Webinar Presentation
Antisense Duchenne’s Trial Set for Approval?
The Road Forward for Antisense
What the FDA Feedback Means for Antisense Therapeutics (ASX:ANP)
The opportunity in rare disease treatment.
Industry Expert Sees the Path Forward for Antisense Therapeutics
Antisense Therapeutics Limited (ASX: ANP) - Hidden Gems Webinar Presentation - 5/2/21
Antisense Therapeutics - Price Target Raised from $0.305 to $0.43
What's next for Antisense Therapeutics?
Corporate Connect Analyst Marc Sinatra Discusses Antisense Therapeutics (ASX:ANP)
Antisense Eyes A Golden Ticket In The US
Antisense Therapeutics - ShareCafe Hidden Gems Webinar Presentation


And a Door Opens Wide
Potential Competitor on the Canvas
FDA Feedback as Good As It Gets
Paediatric Investigation Plan Almost Certain To Get the Tick and Other Notable Events
Comprehensive Research Report
Biopharmas Hit, but Buying Opportunities Created Antisense (ANP) & Kazia (KZA), Two Companies To Build Your Biopharma Portfolio Around
Antisense Therapeutics (ANP) Taking a Quick Approach to Long COVID